Table 1.
Baseline data, medications and comorbidities of the study population
| Variable | |
| Age, years | 73 (63–78) |
| Women, n (%) | 78 (47) |
| Body mass index (kg/m2) | 28.7±5.3 |
| Systolic blood pressure (mm Hg) | 150±22 |
| Diastolic blood pressure (mm Hg) | 83±11 |
| Glomerular filtration rate (mL/min)* | 89 (68–109) |
| Haemoglobin (g/L) | 144±15 |
| N-terminal pro-brain natriuretic peptide (ng/L) | 295 (66–864) |
| NYHA functional class | |
| I, n (%) | 63 (37) |
| II, n (%) | 80 (47) |
| III, n (%) | 12 (7) |
| IV, n (%) | 11 |
| Diuretics, n (%) | 41 (25) |
| Beta-blockers, n (%) | 51 (31) |
| ACE inhibitor or angiotensin receptor blocker, n (%) | 32 (19) |
| Atrial fibrillation, n (%) | 49 (29) |
| Chronic obstructive pulmonary disease/asthma, n (%) | 26 (16) |
| Diabetes mellitus type 2, n (%) | 23 (14) |
| Coronary artery disease, n (%) | 19 (11) |
Normally distributed data are expressed as mean±SD. Skewed data are presented as median (IQR). Proportions are presented as n (%). Medications refer to the current use.
*Calculated by the Cockcroft-Gault equation.
NYHA, New York Heart Association.